MDCX Latest Press Releases

-- November 4, 2026 --

Medicus Pharma to Host Third Quarter 2026 Financial Performance and Business Update Call on November 9, 2026 Globe Newswire 4:05 PM

Medicus Pharma Announces Proposed SkinJect Business Combination and Concurrent Financing Globe Newswire 8:30 AM

-- October 27, 2026 --

Medicus Pharma to Present at BioFuture and Global Biotechnology Summit Globe Newswire 7:30 AM

-- October 26, 2026 --

Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement Globe Newswire 7:30 AM

-- October 8, 2026 --

Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value Globe Newswire 8:00 AM

-- September 29, 2026 --

Medicus Pharma Submits Optimized Teverelix Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer Globe Newswire 7:30 AM

-- September 21, 2026 --

Medicus Pharma Announces Exclusive Development Focus for SkinJect in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment Globe Newswire 7:30 AM

-- September 10, 2026 --

Medicus Pharma Publishes Abridged Final Phase 2 SkinJect Clinical Study Report (CSR) Results Identifying 200 g D-MNA Patch as the Lead Development Dose Globe Newswire 7:30 AM

-- September 8, 2026 --

Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company Globe Newswire 7:30 AM

-- August 12, 2026 --

Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update ACCESS Newswire 6:00 PM

-- August 3, 2026 --

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom Globe Newswire 7:30 AM

-- July 31, 2026 --

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix in Women with Endometriosis Globe Newswire 7:30 AM

-- July 27, 2026 --

Medicus Pharma Receives FDA 'Study May Proceed' Letter for NDA-Enabling Registrational SkinJect Study in Patients with Gorlin Syndrome Globe Newswire 8:17 AM

-- July 16, 2026 --

Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix Novel Study in Acute Urinary Retention Globe Newswire 7:30 AM

-- June 22, 2026 --

Medicus Pharma to Showcase SkinJect Registrational Strategy and Teverelix Precision Medicine Program at Bio International 2026 Globe Newswire 7:30 AM

-- June 15, 2026 --

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect in Gorlin Syndrome Globe Newswire 7:30 AM

-- June 11, 2026 --

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix in Endometriosis utilizing the Emirati Genome Program Globe Newswire 7:30 AM

-- June 8, 2026 --

Medicus Pharma Advances Teverelix Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes